|
411 Companies |
|
276 Products |
|
276 Products |
|
144 Mechanisms of Action |
|
556 Trials |
|
45670 News |
|
| «12...622623624625626627628629630631632...643644» |
- Halaven (eribulin mesylate) / Eisai
Trial initiation date: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer (clinicaltrials.gov) - Jan 21, 2014
P1, N=24, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Initiation date: Oct 2011 --> Oct 2012
- |||||||||| Lonquex (lipegfilgrastim biosimilar) / Teva
New P3 trial: A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (clinicaltrials.gov) - Jan 21, 2014
P3, N=150, Recruiting, Sponsor: Merckle GmbH
- bendamustine / Generic mfg.
New P2 trial: Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 21, 2014
P2, N=10, Recruiting, Sponsor: SymBio Pharmaceuticals
- Halaven (eribulin mesylate) / Eisai
Enrollment closed: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer (clinicaltrials.gov) - Jan 21, 2014
P1, N=24, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Initiation date: Oct 2011 --> Oct 2012 Recruiting --> Active, not recruiting
- sorafenib / Generic mfg.
Trial completion: Sorafenib. ICORG 06-41, V4 (clinicaltrials.gov) - Jan 21, 2014
P2, N=54, Completed, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Victrelis (boceprevir) / Roche, Merck (MSD)
Enrollment change, Combination therapy: Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) (clinicaltrials.gov) - Jan 20, 2014
P3, N=270, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=390 --> 270
- | Jakafi (ruxolitinib) / Incyte
New P2 trial, Metastases: Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca (clinicaltrials.gov) - Jan 20, 2014
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
- ||||| Victrelis (boceprevir) / Roche, Merck (MSD)
Enrollment closed, Combination therapy: Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) (clinicaltrials.gov) - Jan 20, 2014
P3, N=270, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=390 --> 270 Recruiting --> Active, not recruiting
- indusatumab vedotin (TAK-264) / Takeda
Metastases: Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C (clinicaltrials.gov) - Jan 19, 2014
P1, N=41, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting N=60 --> 41
- pazopanib / Generic mfg.
Enrollment change: Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors (clinicaltrials.gov) - Jan 19, 2014
P1, N=51, Recruiting, Sponsor: National Cancer Institute (NCI)
N=60 --> 41 N=35 --> 51
- bendamustine / Generic mfg.
Enrollment open: Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 19, 2014
P2, N=10, Recruiting, Sponsor: SymBio Pharmaceuticals
N=35 --> 51 Not yet recruiting --> Recruiting
- pazopanib / Generic mfg.
Enrollment open: Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors (clinicaltrials.gov) - Jan 19, 2014
P1, N=51, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting
- indusatumab vedotin (TAK-264) / Takeda
Metastases: Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C (clinicaltrials.gov) - Jan 19, 2014
P1, N=41, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Suspended --> Recruiting Recruiting --> Active, not recruiting
- ||||| Ibrance (palbociclib) / Pfizer
New P2 trial: Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer (clinicaltrials.gov) - Jan 16, 2014
P2, N=120, Recruiting, Sponsor: Dana-Farber Cancer Institute
- Calquence (acalabrutinib) / AstraZeneca
Enrollment open: ACE-CL-001: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia (clinicaltrials.gov) - Jan 16, 2014
P1, N=36, Recruiting, Sponsor: Acerta Pharma BV
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Karenitecin (cositecan) / BioNumerik
Trial completion: Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov) - Jan 16, 2014
P3, N=509, Completed, Sponsor: BioNumerik Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Metastases: A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (clinicaltrials.gov) - Jan 15, 2014
P1/2, N=320, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Daurismo (glasdegib) / Pfizer
New P1 trial: A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies (clinicaltrials.gov) - Jan 15, 2014
P1, N=24, Recruiting, Sponsor: Pfizer
- ||| LY3009120 / Eli Lilly
Enrollment open, Metastases: A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body (clinicaltrials.gov) - Jan 14, 2014
P1, N=100, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment open, Metastases: Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer (clinicaltrials.gov) - Jan 14, 2014
P1/2, N=71, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- alisertib (MLN8237) / Puma
Trial suspension, Combination therapy: Study of MLN8237 in Combination With Irinotecan and Temozolomide (clinicaltrials.gov) - Jan 13, 2014
P1/2, N=44, Suspended, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Not yet recruiting --> Recruiting Recruiting --> Suspended
- Votrient (pazopanib) / Novartis, BeiGene
Trial suspension, Metastases: Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer (clinicaltrials.gov) - Jan 13, 2014
P1, N=44, Suspended, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Suspended Active, not recruiting --> Suspended
- brostallicin (PNU-166196) / SOBI
Trial completion: Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 13, 2014
P1/2, N=3, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Suspended Active, not recruiting --> Completed
- ||| GSK2879552 / GSK
New P1 trial: Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma (clinicaltrials.gov) - Jan 9, 2014
P1, N=80, Recruiting, Sponsor: GlaxoSmithKline
- |||| Tepmetko (tepotinib) / EMD Serono
Enrollment open, Metastases: Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) (clinicaltrials.gov) - Jan 9, 2014
P1/2, N=200, Recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| alisertib (MLN8237) / Puma
Enrollment closed: Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies (clinicaltrials.gov) - Jan 9, 2014
P1/2, N=273, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- |||| Extimia (empegfilgrastim biosimilar) / Biocad
Trial completion: Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer (clinicaltrials.gov) - Jan 9, 2014
P2, N=60, Completed, Sponsor: Biocad
Completed --> Active, not recruiting Active, not recruiting --> Completed
- ||| GSK2849330 / GSK
Enrollment open, Metastases: Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors (clinicaltrials.gov) - Jan 8, 2014
P1, N=155, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| vedroprevir (GS 9451) / Gilead, tegobuvir (GS 9190) / Gilead
Enrollment change, Combination therapy: A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys (clinicaltrials.gov) - Jan 7, 2014
P2, N=245, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting N=320 --> 245
- |||| vedroprevir (GS 9451) / Gilead, tegobuvir (GS 9190) / Gilead
Trial completion, Combination therapy: A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys (clinicaltrials.gov) - Jan 7, 2014
P2, N=245, Completed, Sponsor: Gilead Sciences
N=320 --> 245 Active, not recruiting --> Completed
- ||| Trial completion, Metastases: A Study of IMC-RON8 in Advanced Solid Tumors (clinicaltrials.gov) - Jan 7, 2014
P1, N=52, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neugranin (balugrastim biosimilar) / Teva
Trial initiation date: Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors (clinicaltrials.gov) - Jan 6, 2014
P2, N=36, Not yet recruiting, Sponsor: Teva Pharmaceutical Industries
Active, not recruiting --> Completed Initiation date: Dec 2013 --> Jun 2014
- | Calquence (acalabrutinib) / AstraZeneca
New P1 trial: ACE-CL-001: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia (clinicaltrials.gov) - Jan 6, 2014
P1, N=36, Recruiting, Sponsor: Acerta Pharma BV
- Orencia (abatacept) / BMS
Trial initiation date, Post-transplantation: Bone Marrow Transplant With Abatacept for Non-Malignant Diseases (clinicaltrials.gov) - Jan 5, 2014
P1, N=20, Recruiting, Sponsor: Emory University
Initiation date: Dec 2013 --> Jun 2014 Initiation date: Sep 2013 --> Jan 2014
- | New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: MOST plus: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (clinicaltrials.gov) - Jan 5, 2014
P2, N=560, Recruiting, Sponsor: Centre Leon Berard
- Orencia (abatacept) / BMS
Enrollment open, Post-transplantation: Bone Marrow Transplant With Abatacept for Non-Malignant Diseases (clinicaltrials.gov) - Jan 5, 2014
P1, N=20, Recruiting, Sponsor: Emory University
Initiation date: Sep 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 5, 2014
P1, N=32, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Odomzo (sonidegib) / Sun Pharma
New P1 trial, Combination therapy, Metastases: EDALINE: Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients (clinicaltrials.gov) - Jan 2, 2014
P1, N=18, Not yet recruiting, Sponsor: Spanish Breast Cancer Research Group
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion: OTOHTPF: Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=130, Completed, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Active, not recruiting --> Completed Recruiting --> Completed
- crenolanib (ARO-002) / AROG
Enrollment closed: PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma (clinicaltrials.gov) - Dec 26, 2013
P1, N=56, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed Recruiting --> Active, not recruiting
- irinotecan / Generic mfg.
Enrollment closed, Metastases: Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Dec 25, 2013
P2, N=500, Active, not recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Combination therapy: A Confirmation Study of Eribulin in Combination With Capecitabine (clinicaltrials.gov) - Dec 19, 2013
P1/2, N=116, Active, not recruiting, Sponsor: Eisai Limited
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| tegobuvir (GS 9190) / Gilead, GS 9256 / Gilead
Trial completion, Combination therapy: A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys (clinicaltrials.gov) - Dec 19, 2013
P2, N=324, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Campath (alemtuzumab) / Sanofi
Trial termination: Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) (clinicaltrials.gov) - Dec 17, 2013
P2, N=7, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Terminated; Low Accrual
- Campath (alemtuzumab) / Sanofi
Enrollment change: Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) (clinicaltrials.gov) - Dec 17, 2013
P2, N=7, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Terminated; Low Accrual N=29 --> 7
- |||| Vesanoid (tretinoin) / Roche
Enrollment open: Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 17, 2013
P1/2, N=70, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=29 --> 7 Not yet recruiting --> Recruiting
- |||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, Combination therapy, Metastases: Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient (clinicaltrials.gov) - Dec 17, 2013
P1/2, N=90, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Xospata (gilteritinib) / Astellas
New P1/2 trial: Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2013
P1/2, N=145, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
- ||| LY3009120 / Eli Lilly
New P1 trial, Metastases: A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body (clinicaltrials.gov) - Dec 16, 2013
P1, N=100, Recruiting, Sponsor: Eli Lilly and Company
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Surgery, Stroma: Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence (clinicaltrials.gov) - Dec 10, 2013
P3, N=330, Not yet recruiting, Sponsor: AB Science